Based on the Olema Pharmaceuticals Inc stock forecast from 4 analysts, the average analyst target price for Olema Pharmaceuticals Inc is USD 28.67 over the next 12 months. Olema Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Olema Pharmaceuticals Inc is Slightly Bearish, which is based on 2 positive signals and 4 negative signals. At the last closing, Olema Pharmaceuticals Inc’s stock price was USD 4.21. Olema Pharmaceuticals Inc’s stock price has changed by +37.58% over the past week, -4.54% over the past month and -61.20% over the last year.
Past 12 monthsNext 12 months
No recent analyst target price found for Olema Pharmaceuticals Inc
No recent average analyst rating found for Olema Pharmaceuticals Inc
Company Overview Olema Pharmaceuticals Inc
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors palbociclib and ribociclib, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, and with an mTOR inhibitor everolimus that is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 for patients with ER+/HER2- metastatic breast cancer and other cancers which is in Phase 1 clinical trial. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California. Read Less
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER de...Read More
Frequently Asked Questions About Olema Pharmaceuticals Inc (OLMA) Stock
Based on ratings from 4 analysts Olema Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 6 buy, sell and hold ratings.
Unfortunately we do not have enough data on OLMA's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for OLMA is USD 28.67 over the next 12 months. The maximum analyst target price is USD 30 while the minimum anlayst target price is USD 25.
Unfortunately we do not have enough data on OLMA's stock to indicate if its overvalued.
The last closing price of OLMA's stock was USD 4.21.
The most recent market capitalization for OLMA is USD 0.26B.
Based on targets from 4 analysts, the average taret price for OLMA is projected at USD 28.67 over the next 12 months.
This means that OLMA's stock price may go up by +580.92% over the next 12 months.
We can't find any ETFs which contains Olema Pharmaceuticals Inc's stock.
As per our most recent records Olema Pharmaceuticals Inc has 96 Employees.
Olema Pharmaceuticals Inc's registered address is 780 Brannan Street, San Francisco, CA, United States, 94103.
You can get more information about it from Olema Pharmaceuticals Inc's website at https://olema.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Olema Pharmaceuticals Inc (OLMA) Stock
Based on ratings from 4 analysts Olema Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 6 buy, sell and hold ratings.
Unfortunately we do not have enough data on OLMA's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for OLMA is USD 28.67 over the next 12 months. The maximum analyst target price is USD 30 while the minimum anlayst target price is USD 25.
Unfortunately we do not have enough data on OLMA's stock to indicate if its overvalued.
The last closing price of OLMA's stock was USD 4.21.
The most recent market capitalization for OLMA is USD 0.26B.
Based on targets from 4 analysts, the average taret price for OLMA is projected at USD 28.67 over the next 12 months.
This means that OLMA's stock price may go up by +580.92% over the next 12 months.
We can't find any ETFs which contains Olema Pharmaceuticals Inc's stock.
As per our most recent records Olema Pharmaceuticals Inc has 96 Employees.
Olema Pharmaceuticals Inc's registered address is 780 Brannan Street, San Francisco, CA, United States, 94103.
You can get more information about it from Olema Pharmaceuticals Inc's website at https://olema.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for OLMA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
